Strategies of targeting CK2 in drug discovery: challenges, opportunities, and emerging prospects
Y Chen, Y Wang, J Wang, Z Zhou, S Cao… - Journal of Medicinal …, 2023 - ACS Publications
CK2 (casein kinase 2) is a serine/threonine protein kinase that is ubiquitous in eukaryotic
cells and plays important roles in a variety of cellular functions, including cell growth …
cells and plays important roles in a variety of cellular functions, including cell growth …
Role of protein kinase CK2 in antitumor drug resistance
Drug resistance represents the major reason of pharmacological treatment failure. It is
supported by a broad spectrum of mechanisms, whose molecular bases have been …
supported by a broad spectrum of mechanisms, whose molecular bases have been …
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators
IF Zattoni, LC Delabio, J de Paula Dutra, DH Kita… - European journal of …, 2022 - Elsevier
The primary source of failure of cancer therapies is multidrug resistance (MDR), which can
be caused by different mechanisms, including the overexpression of ABC transporters in …
be caused by different mechanisms, including the overexpression of ABC transporters in …
ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein inhibition through machine learning
Breast cancer resistance protein (BCRP/ABCG2), an ATP-binding cassette (ABC) efflux
transporter, plays a critical role in multi-drug resistance (MDR) to anti-cancer drugs and drug …
transporter, plays a critical role in multi-drug resistance (MDR) to anti-cancer drugs and drug …
Recent development in indole derivatives as anticancer agents for breast cancer
K Kaur, V Jaitak - Anti-Cancer Agents in Medicinal Chemistry …, 2019 - ingentaconnect.com
Background: Breast Cancer (BC) is the second most common cause of cancer related
deaths in women. Due to severe side effects and multidrug resistance, current therapies like …
deaths in women. Due to severe side effects and multidrug resistance, current therapies like …
Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development
ATP-binding cassette (ABC) transporters are pivotal for cell detoxification and survival.
Overexpression of ABC transporter in tumor cells lead to chemoresistance through the efflux …
Overexpression of ABC transporter in tumor cells lead to chemoresistance through the efflux …
ABCG2/BCRP: specific and nonspecific modulators
D Peña‐Solórzano, SA Stark, B König… - Medicinal research …, 2017 - Wiley Online Library
Multidrug resistance (MDR) in cancer cells is the development of resistance to a variety of
structurally and functionally nonrelated anticancer drugs. This phenomenon has become a …
structurally and functionally nonrelated anticancer drugs. This phenomenon has become a …
Current research on anti-breast cancer synthetic compounds
J Liu, B Ming, GH Gong, D Wang, GL Bao, LJ Yu - RSC advances, 2018 - pubs.rsc.org
Breast cancer (BC) is the most common cancer for females and its incidence tends to
increase year by year. Currently, the backbone of therapy for BC is mainly chemotherapy …
increase year by year. Currently, the backbone of therapy for BC is mainly chemotherapy …
Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles
DH Kita, N Guragossian, IF Zattoni, VR Moure… - Scientific Reports, 2021 - nature.com
The ATP-binding cassette transporter ABCG2 mediates the efflux of several
chemotherapeutic drugs, contributing to the development of multidrug resistance (MDR) in …
chemotherapeutic drugs, contributing to the development of multidrug resistance (MDR) in …
Flavonoid monomers as potent, nontoxic, and selective modulators of the breast cancer resistance protein (ABCG2)
ILK Wong, X Zhu, KF Chan, Z Liu… - Journal of medicinal …, 2021 - ACS Publications
We synthesize various substituted triazole-containing flavonoids and identify potent,
nontoxic, and highly selective BCRP inhibitors. Ac18Az8, Ac32Az19, and Ac36Az9 possess …
nontoxic, and highly selective BCRP inhibitors. Ac18Az8, Ac32Az19, and Ac36Az9 possess …